CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease in Patients With Early Systemic Sclerosis: Data From Two Independent Cohorts

Arthritis and Rheumatology

Volumn 69, Issue 9, 2017, Pages 1871-1878

  Wu, Minghua ^a   Baron, Murray ^b   Pedroza, Claudia ^a   Salazar, Gloria A ^a   Ying, Jun ^a   Charles, Julio ^a   Agarwal, Sandeep K ^c   Hudson, Marie ^d   Pope, Janet ^e   Zhou, Xiaodong ^a   Reveille, John D ^a   Fritzler, Marvin J ^f   Mayes, Maureen D ^a   Assassi, Shervin ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

^f UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL11 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; BIOLOGICAL MARKER; CCL2 PROTEIN, HUMAN; CYTOKINE;

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; INTERSTITIAL LUNG DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC SCLEROSIS; TH1 TH2 BALANCE; ADULT; BLOOD; CANADA; COMPLICATION; FEMALE; LUNG DISEASES, INTERSTITIAL; MALE; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VITAL CAPACITY;

ADULT; BIOMARKERS; CANADA; CHEMOKINE CCL2; COHORT STUDIES; CYTOKINES; DISEASE PROGRESSION; FEMALE; HUMANS; LONGITUDINAL STUDIES; LUNG DISEASES, INTERSTITIAL; MALE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SCLERODERMA, SYSTEMIC; VITAL CAPACITY;

EID: 85028396582     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.40171     Document Type: Article

References (26)

1. Elhai M, Meune C, Avouac J, Kahan A, Allanore Y. Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2012;51:1017–26.
2. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007;66:940–4.
3. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010;69:1809–15.
4. Assassi S, Sharif R, Lasky RE, McNearney TA, Estrada YM, Draeger H, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010;12:R166.
5. Liu X, Mayes MD, Pedroza C, Draeger HT, Gonzalez EB, Harper BE, et al. Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis? Arthritis Care Res (Hoboken) 2013;65:1375–80.
6. De LA, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, et al. Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. J Rheumatol 2013;40:435–46.
7. Gourh P, Arnett FC, Assassi S, Tan FK, Huang M, Diekman L, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009;11:R147.
8. Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2013;65:2737–47.
9. Alhajeri H, Hudson M, Fritzler M, Pope J, Tatibouet S, Markland J, et al. 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken) 2015;67:582–7.
10. Furst D, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, et al. Systemic sclerosis: continuing progress in developing clinical measures of response. J Rheumatol 2007;34:1194–200.
11. Rizopoulos D. An R package for the joint modelling of longitudinal and time-to-event data. J Stat Software 2010;35:1–33.
12. Rizopoulos D, Verbeke G, Molenberghs G. Multiple-imputation-based residuals and diagnostic plots for joint models of longitudinal and survival outcomes. Biometrics 2010;66:20–9.
13. Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 2016;387:2630–40.
14. Assassi S, Wu M, Tan FK, Chang J, Graham TA, Furst DE, et al. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum 2013;65:2917–27.
15. Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, Hanitsch LG, et al. Bronchoalveolar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 2009;11:R111.
16. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fibroblast collagen and transforming growth factor β1 gene expression by monocyte chemoattractant protein-1 via specific receptors. J Biol Chem 1996;271:17779–84.
17. Distler O, Pap T, Kowal-Bielecka O, Meyringer R, Guiducci S, Landthaler M, et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001;44:2665–78.
18. Carulli MT, Ong VH, Ponticos M, Shiwen X, Abraham DJ, Black CM, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005;52:3772–82.
19. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003;121:510–6.
20. Trial J, Cieslik KA, Haudek SB, Duerrschmid C, Entman ML. Th1/M1 conversion to Th2/M2 responses in models of inflammation lacking cell death stimulates maturation of monocyte precursors to fibroblasts. Front Immunol 2013;4:287.
21. Higashi-Kuwata N, Jinnin M, Makino T, Fukushima S, Inoue Y, Muchemwa FC, et al. Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis. Arthritis Res Ther 2010;12:R128.
22. Nakagome K, Dohi M, Okunishi K, Tanaka R, Miyazaki J, Yamamoto K. In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-β in the lung. Thorax 2006;61:886–94.
23. Garantziotis S, Brass DM, Savov J, Hollingsworth JW, McElvania-TeKippe E, Berman K, et al. Leukocyte-derived IL-10 reduces subepithelial fibrosis associated with chronically inhaled endotoxin. Am J Respir Cell Mol Biol 2006;35:662–7.
24. Elhaj M, Charles J, Pedroza C, Liu X, Zhou X, Estrada YM, et al. Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis? J Rheumatol 2013;40:1114–20.
25. Kuwana M, Shirai Y, Takeuchi T. Elevated serum Krebs von den Lungen-6 in early disease predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease. J Rheumatol 2016;43:1825–31.
26. Chowdhury F, Williams A, Johnson P. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods 2009;340:55–64.